Results from ABSORB Trial Positive Says Abbott


October 18, 2007

October 18, 2007 - Abbott announced that trial results for ABSORB, the world’s first clinical trial evaluating the safety and performance of a fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease, are positive.

ABSORB’s nine-month results from the first 30 patients in the trial demonstrated no stent thrombosis and a low (4.0 percent, one patient) rate of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment.

Abbott's everolimus eluting bioabsorbable stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbott's bioabsorbable stent is designed to restore blood flow by propping a clogged vessel open, and provide support until the blood vessel heals. Unlike a metallic stent however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac Events (MACE) and no late stent thrombosis in patients treated with either Abbott's XIENCE V Everolimus Eluting Coronary Stent System or its MULTI-LINK VISION metallic coronary stent.

For more information: